- Home
- COSM vs NRSN Comparison
COSM vs NRSN Comparison
Compare COSM & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COSM
- NRSN
- Stock Information
- Founded
- COSM 2009
- NRSN 2017
- Country
- COSM United States
- NRSN Israel
- Employees
- COSM N/A
- NRSN N/A
- Industry
- COSM Other Pharmaceuticals
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- COSM Health Care
- NRSN Health Care
- Exchange
- COSM Nasdaq
- NRSN Nasdaq
- Market Cap
- COSM 32.3M
- NRSN 29.8M
- IPO Year
- COSM 2013
- NRSN 2021
- Fundamental
- Price
- COSM $0.75
- NRSN $0.98
- Analyst Decision
- COSM
- NRSN Buy
- Analyst Count
- COSM 0
- NRSN 2
- Target Price
- COSM N/A
- NRSN $14.00
- AVG Volume (30 Days)
- COSM 462.3K
- NRSN 203.5K
- Earning Date
- COSM 11-14-2025
- NRSN 12-17-2025
- Dividend Yield
- COSM N/A
- NRSN N/A
- EPS Growth
- COSM N/A
- NRSN N/A
- EPS
- COSM N/A
- NRSN N/A
- Revenue
- COSM $55,093,442.00
- NRSN N/A
- Revenue This Year
- COSM $28.14
- NRSN N/A
- Revenue Next Year
- COSM N/A
- NRSN N/A
- P/E Ratio
- COSM N/A
- NRSN N/A
- Revenue Growth
- COSM N/A
- NRSN N/A
- 52 Week Low
- COSM $0.28
- NRSN $0.80
- 52 Week High
- COSM $1.32
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- COSM 37.07
- NRSN 37.32
- Support Level
- COSM $0.70
- NRSN $0.89
- Resistance Level
- COSM $0.77
- NRSN $0.97
- Average True Range (ATR)
- COSM 0.08
- NRSN 0.07
- MACD
- COSM -0.01
- NRSN -0.01
- Stochastic Oscillator
- COSM 21.30
- NRSN 26.22
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.